Related Experiment Video
Updated: Aug 5, 2026
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical
Babita Kataria1, Asima Mukhopadhyay2, Ana Oaknin3
1Department of Medical Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
The Lancet. Oncology
|July 27, 2026
Summary
The Gynecologic Cancer InterGroup (GCIG) established consensus on 16 statements for cervical cancer clinical trials. This collaboration addresses diagnosis, staging, and treatment, aiming to improve global research outcomes.
Area of Science:
- Oncology
- Clinical Trials
- Gynaecological Cancers
Background:
- The Gynecologic Cancer InterGroup (GCIG) has a history of fostering collaboration in ovarian and endometrial cancer clinical trials.
- Standardized clinical trial conduct is crucial for advancing gynaecological cancer patient outcomes.
Purpose of the Study:
- To establish a consensus on critical aspects of cervical cancer clinical research.
- To identify essential questions and unmet needs in the field of cervical cancer.
Main Methods:
- Convened the inaugural Cervical Cancer Consensus Conference in Clinical Research.
- Involved 33 GCIG member groups, patient advocates, young investigators, and international representatives.
- Developed, refined, and adopted 16 consensus statements across four key topic areas.
Main Results:
- Achieved consensus on all 16 statements covering diagnosis, staging, early-stage, locally advanced, and persistent/recurrent disease.
- Identified and tabulated specific areas of unmet need in cervical cancer research.
- Demonstrated high agreement rates through rigorous debate and discussion.
Conclusions:
- The consensus process highlights a strong commitment to harmonized, inclusive, and pragmatic academic clinical trials globally.
- The established statements provide a framework for future cervical cancer research.
- Addressing identified unmet needs is paramount for improving patient care and outcomes.
Related Concept Videos
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...